Effect of ryanodine receptor mutations on interleukin-6 release and intracellular calcium homeostasis in human myotubes from malignant hyperthermia-susceptible individuals and patients affected by central core disease.
In this study we report for the first time the functional properties of human myotubes isolated from patients harboring the native RYR1 I4898T and R4893W mutations linked to central core disease. We examined two aspects of myotube physiology, namely excitation-contraction and excitation-secretion coupling. Our results show that upon activation of the ryanodine receptor (RYR), myotubes release interleukin-6 (IL-6); this was dependent on de novo protein synthesis and could be blocked by dantrolene and cyclosporine. Myotubes from the two patients affected by central core disease showed a 4-fold increase in the release of the inflammatory cytokine IL-6, compared with cells derived from control or malignant hyperthermia susceptible individuals. All tested myotubes released calcium from intracellular stores upon stimulation via surface membrane depolarization or direct RYR activation by 4-chloro-m-cresol. The functional impact on calcium release of RYR1 mutations linked to central core disease or malignant hyperthermia is different: human myotubes carrying the malignant hyperthermia-linked RYR1 mutation V2168M had a shift in their sensitivity to the RYR agonist 4-chloro-m-cresol to lower concentrations, whereas human myotubes harboring C-terminal mutations linked to central core disease exhibited reduced [Ca2+]i increase in response to 4-chloro-m-cresol, caffeine, and KCl. Taken together, these results suggest that abnormal release of calcium via mutated RYR enhances the production of the inflammatory cytokine IL-6, which may in turn affect signaling pathways responsible for the trophic status of muscle fibers.
Ducreux
Sylvie
S
Department of Anaesthesia, Kantonsspital Basel, 4031, Switzerland.
Zorzato
Francesco
F
Müller
Clemens
C
Sewry
Caroline
C
Muntoni
Francesco
F
Quinlivan
Ros
R
Restagno
Gabriella
G
Girard
Thierry
T
Treves
Susan
S
D002110:Caffeine / Q000494:pharmacology; D002118:Calcium / Q000502:physiology*; D002478:Cells, Cultured; D003513:Cycloheximide / Q000494:pharmacology; D016572:Cyclosporine / Q000494:pharmacology; D004198:Disease Susceptibility; D006706:Homeostasis; D006801:Humans; D015850:Interleukin-6 / Q000378:metabolism*; D007700:Kinetics; D008305:Malignant Hyperthermia / Q000235:genetics* / Q000276:immunology; D018485:Muscle Fibers, Skeletal / Q000187:drug effects / Q000276:immunology* / Q000502:physiology*; D020512:Myopathy, Central Core / Q000235:genetics* / Q000276:immunology; D012016:Reference Values; D019837:Ryanodine Receptor Calcium Release Channel / Q000235:genetics*
D015850:Interleukin-6; D019837:Ryanodine Receptor Calcium Release Channel; D002110:Caffeine; D016572:Cyclosporine; D003513:Cycloheximide; D002118:Calcium